18F-BPA as a surrogate tracer for BPA in BNCT: comparative analysis of transport mechanisms and biodistribution
Journal of Radiation Research · 2026
DOI: 10.1093/jrr/rraf070 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Radiation Research, 2026. Verfasst von Li Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Neuboron Bio-SciTech Co., Ltd., Floor 1 and 5, Building B6, Xiamen Biology Medicine Industrial Park, 2060 West Wengjiao Road, Haicang Dist., Xiamen C…. Hauptthemen laut MEDLINE: Boron Neutron Capture Therapy, Phenylalanine, Boron Compounds, Fluorine Radioisotopes. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program.
Abstract (Originalsprache)
4-Borono-L-phenylalanine (BPA) is a key 10B carrier used in boron neutron capture therapy (BNCT), while its PET tracer analogue, 4-borono-2-18F-fluoro-L-phenylalanine (18F-BPA), enables non-invasive visualization of tumour boron uptake. Since BNCT efficacy depends on precise tumour boron accumulation, we evaluated whether 18F-BPA mirrors BPA’s transport and biodistribution. In vitro, BPA exhibited a highly consistent uptake profile with its non-radioactive fluorinated analogue, 2-19F-4-borono-L-phenylalanine (19F-BPA), across nine cancer cell lines (r = 0.9455, P < 0.001) and tri-iodothyronine (T3)-mediated LAT-1 inhibition markedly reduced the uptake of both BPA and 19F-BPA. In vivo, BPA and 18F-BPA showed predominant accumulation in the kidneys and pancreas in Sprague–Dawley rats, with substantially lower levels detected in other organs. Importantly, in tumour-bearing mice, the time-concentration curve of BPA and the time-activity curve of 18F-BPA in tumours were found to be highly consistent, and showed a corresponding relationship between BPA concentration and 18F-BPA activity in terms of accumulation in tumour, blood, and muscle (r = 0.9623, P < 0.0001). Collectively, these findings confirm that BPA and 18F-BPA not only share LAT-1-mediated transport mechanisms, but also exhibit similar pharmacokinetics and tumour-specific accumulation. This substantiates the use of 18F-BPA as a reliable surrogate for visualizing BPA biodistribution and optimizing patient-specific BNCT treatment planning.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuboron Bio-SciTech Co., Ltd., Floor 1 and 5, Building B6, Xiamen Biology Medicine Industrial Park, 2060 West Wengjiao Road, Haicang Dist., Xiamen City, Fujian Province, 361000, People's Republic of China.
- Neuboron Therapy System Ltd. Floor 1 and 5, Building B6, Xiamen Biology Medicine Industrial Park, 2060 West Wengjiao Road, Haicang Dist., Xiamen City, Fujian Province, 361000, People's Republic of China.
ORCID-Profile: Li Li, Ping Zhou, Yuanhao Liu
Förderung
- National Key Research and Development Program
Zitieren
APA
Li, L., Sun, X., Lin, F., Zhang, T., Zhou, P., & Liu, Y. (2026). 18F-BPA as a surrogate tracer for BPA in BNCT: comparative analysis of transport mechanisms and biodistribution. Journal of Radiation Research. https://doi.org/10.1093/jrr/rraf070
Vancouver
Li L, Sun X, Lin F, Zhang T, Zhou P, Liu Y. 18F-BPA as a surrogate tracer for BPA in BNCT: comparative analysis of transport mechanisms and biodistribution. Journal of Radiation Research. 2026. doi:10.1093/jrr/rraf070
BibTeX
@article{Li2026,
author = {Li, Li and Sun, Xiaoping and Lin, Fu and Zhang, Tan and Zhou, Ping and Liu, Yuanhao},
title = {18F-BPA as a surrogate tracer for BPA in BNCT: comparative analysis of transport mechanisms and biodistribution},
journal = {Journal of Radiation Research},
year = {2026},
doi = {10.1093/jrr/rraf070}
}
EUVIMED